CorMedix (CRMD) Liabilities and Shareholders Equity (2010 - 2025)

CorMedix (CRMD) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $826.1 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 595.14% year-over-year to $826.1 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 billion (up 514.3% YoY), and the FY2025 full-year result was $826.1 million, up 595.14% from the prior year.
• Liabilities and Shareholders Equity improved to $826.1 million in Q4 2025, from $750.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $826.1 million in Q4 2025 to a low of $57.0 million in Q2 2023.
• A 5-year average of $157.9 million and a median of $76.5 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 22.94% in 2022 and soared 867.78% in 2025, its largest moves.
• Tracing CRMD's Liabilities and Shareholders Equity over 5 years: stood at $68.9 million in 2021, then declined by 10.02% to $62.0 million in 2022, then jumped by 32.27% to $82.1 million in 2023, then jumped by 44.83% to $118.8 million in 2024, then soared by 595.14% to $826.1 million in 2025.
• Business Quant data shows CRMD's Liabilities and Shareholders Equity at $826.1 million in Q4 2025, $750.9 million in Q3 2025, and $252.6 million in Q2 2025.